PREVACID NAPRAPAC 500 (COPACKAGED) Drug Patent Profile
✉ Email this page to a colleague
When do Prevacid Naprapac 500 (copackaged) patents expire, and what generic alternatives are available?
Prevacid Naprapac 500 (copackaged) is a drug marketed by Takeda Pharms Na and is included in one NDA.
The generic ingredient in PREVACID NAPRAPAC 500 (COPACKAGED) is lansoprazole; naproxen. There are fifty-six drug master file entries for this compound. Additional details are available on the lansoprazole; naproxen profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PREVACID NAPRAPAC 500 (COPACKAGED)?
- What are the global sales for PREVACID NAPRAPAC 500 (COPACKAGED)?
- What is Average Wholesale Price for PREVACID NAPRAPAC 500 (COPACKAGED)?
Summary for PREVACID NAPRAPAC 500 (COPACKAGED)
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | PREVACID NAPRAPAC 500 (COPACKAGED) at DailyMed |
-patent-expirations.png "PREVACID NAPRAPAC 500 (COPACKAGED) drug patent expirations")
US Patents and Regulatory Information for PREVACID NAPRAPAC 500 (COPACKAGED)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Na | PREVACID NAPRAPAC 500 (COPACKAGED) | lansoprazole; naproxen | CAPSULE, DELAYED REL PELLETS, TABLET;ORAL | 021507-004 | Nov 14, 2003 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for PREVACID NAPRAPAC 500 (COPACKAGED)
See the table below for patents covering PREVACID NAPRAPAC 500 (COPACKAGED) around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 42554 | ⤷ Start Trial | |
| Australia | 4589585 | ⤷ Start Trial | |
| Australia | 570130 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PREVACID NAPRAPAC 500 (COPACKAGED)
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0174726 | SPC/GB94/011 | United Kingdom | ⤷ Start Trial | SPC/GB94/011, EXPIRES: 20051210 |
| 0174726 | 93C0021 | Belgium | ⤷ Start Trial | PRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch